Renovascular and renoprotective properties of telmisartan: clinical utility by Ladino, Marco & Schulman, Ivonne Hernandez
© 2010 Ladino and Schulman, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease 2010:3 33–38
International Journal of Nephrology and Renovascular Disease
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
33
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Renovascular and renoprotective properties  




Veterans Affairs Medical Center 
and Division of Nephrology and 
Hypertension and Interdisciplinary 
Stem Cell Institute, University of 
Miami Miller School of Medicine, 
Miami, FL, USA
Correspondence: Ivonne H Schulman
University of Miami Miller School  
of Medicine, Veterans Affairs Medical 
Center, Nephrology-Hypertension 
Section, 1201 NW 16th Street, Room 
A-1009, Miami, FL 33125, USA
Tel +1 305 575 3103
Fax +1 305 575 3378
Email ischulman@med.miami.edu
Abstract: Chronic kidney disease (CKD) affects approximately 26 million adults in the United 
States and millions of others are at increased risk. Type 2 diabetes and hypertension are the two 
main causes of CKD. Blood pressure control is critical to slow the progression of CKD. Despite 
adequate control, however, patients continue to progress to end-stage renal disease. Angiotensin 
receptor blockers (ARBs) are commonly used in the management of hypertension and CKD 
and have been shown to exert renoprotective effects that are in addition to, but independent of, 
blood pressure lowering. Telmisartan is a long-acting ARB with pharmacological properties 
beyond blockade of the angiotensin II type 1 receptor, including activation of the peroxisome 
proliferator activated receptor-γ (PPAR-γ). This article reviews the beneficial renal and vascular 
protective effects of telmisartan.
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Introduction
The incidence and prevalence of essential hypertension continues to rise worldwide. 
Changes in diet, daily physical activity, environment, and lifestyle have made hyper-
tension a more common and difficult to control disease. Of greatest concern are the 
diseases that arise as a consequence of undetected and/or uncontrolled hypertension, 
including cerebro-vascular, coronary artery, peripheral vascular, and chronic kidney 
diseases (CKD).
Many classes of medications are currently used to treat hypertension, such as diuret-
ics, beta-blockers, calcium channel blockers, renin inhibitors, angiotensin converting 
enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Among the 
ARBs there is one medication that has special pharmacological properties in addition 
to blocking the angiotensin II type 1 receptor; this medication is telmisartan. It has 
been shown to lower blood pressure as well as exert cardiovascular and renoprotective 
effects independently of blood pressure reduction.
In the present review we will discuss the pharmacology and the beneficial properties 
of telmisartan in the management of hypertension.
Pharmacology
Angiotensin II is the most studied effector peptide of the renin-angiotensin system. 
It is produced from angiotensin I by ACE and has effects in multiple organs of the 
human body. There are 4 types of angiotensin receptors (AT1, AT2, AT3, AT4). AT1 
is the receptor that enables most of the hemodynamic changes in the body that are International Journal of Nephrology and Renovascular Disease 2010:3 34
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related to angiotensin II, these include vasoconstriction and 
stimulation of aldosterone release (Figure 1). In response to 
angiotensin II, there is an increase in glomerular pressure and 
glomerular permselectivity as well as activation of fibrosis 
and cellular growth in the kidney.
Telmisartan is a non-peptide angiotensin II type 1 recep-
tor (AT1) antagonist with high lipophilicity and the longest 
half-life compared with other ARBs.1,2 Available in oral 
preparation, it is highly bound to plasma proteins (99.5%), 
mainly albumin. It is metabolized by conjugation, is not 
metabolized by the cytochrome P450 system, and is elimi-
nated in feces. It has a greater affinity for the AT1 receptor 
than angiotensin II (3000 fold).
Like ACE inhibitors and other ARBs, telmisartan should 
be avoided in pregnant and nursing patients. The side effects 
are similar to those of other ARBs, including hyperkalemia, 
hypotension, and creatinine elevation due to decrease of 
the glomerular filtration rate. These parameters should be 
  monitor closely after the medication is started. It has minimal 
drug interactions, namely digoxin and lithium levels may 
increase and these should be monitored regularly. After 
administration of telmisartan, levels of angiotensin II, angio-
tensin I, and plasma renin activity are elevated, as reported 
with other ARBs and most likely secondary to blockade of 
the AT1 receptor.
Dosage and tolerability
Dose ranges from 20 to 80 mg per day with an onset of 
action of 1–2 hours. Telmisartan has been shown to have a 
low discontinuation rate among patients. Side effects are less 
when compared to ACE inhibitors and it is an option when 
ACE inhibitors are not tolerated.3,4
Clinical properties
Telmisartan is used in the management of hypertension 
as monotherapy or in combination with other types of 
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  antihypertensive medications. It is well known that ARBs 
are effective in reducing blood pressure as well as target 
organ damage, including left ventricular hypertrophy, stroke, 
proteinuria, and progression of CKD. Moreover, there are 
intrinsic properties that make this group of antihypertensives 
unique. It is known that in addition to ACE, the enzyme chy-
mase influences the production of angiotensin II.5 Chymase 
is produced and stored in mast cells, endothelial cells, and 
mesenchymal cells. It is found in the heart, blood vessels, 
and the kidney.5,6 ACE inhibitors do not inhibit chymase, 
thus angiotensin II can still be produced. ARBs block ACE 
and chymase-derived angiotensin II from activating the AT1 
receptor.5
Metabolic effects
There is evidence that in nondiabetic patients with CKD, 
a syndrome of insulin resistance is present even at the early 
stages of renal dysfunction.7 This renal insulin resistance 
syndrome may contribute to the increased incidence of car-
diovascular events in CKD patients.
The peroxisome proliferator activated receptor (PPAR) 
plays an important role in the metabolism of lipids and 
  carbohydrates and has been implicated in insulin resistance, 
metabolic syndrome, and atherosclerosis. Of the available 
ARBs, telmisartan has the greatest stimulating effect on 
PPAR-γ and this effect decreases insulin resistance, increases 
insulin sensitivity, and reduces dyslipidemia, thereby 
  providing greater target-organ protection.8,9 A recent study 
demonstrated that telmisartan not only increased insulin 
sensitivity but also decreased blood levels of triglyceride 
and free fatty acids; this action on lipid metabolism has been 
attributed to modulation of hepatic PPAR-γ activity.10
Vascular effects
ARBs inhibit the growth of vascular smooth muscle cells 
and there is evidence that telmisartan does this to a greater 
extent.11,12 This effect is related to the blockade of the AT1 
receptor and the activation of PPAR-γ, but there are other 
mechanisms that participate.11,12 Protein kinase B (AKT) is 
a proto-oncogene involved in signaling pathways that control 
cellular growth and differentiation. It has been reported that 
telmisartan inhibits vascular smooth muscle cell proliferation 
by inhibiting AKT activation.12
Renal effects
Although blood pressure reduction directly contributes to 
renoprotection, including reduction in proteinuria and slow-
ing of CKD progression, ARBs and ACE inhibitors exert 
additional blood pressure-independent renoprotective effects 
via inhibition of the renin-angiotensin-aldosterone system 
(RAAS).1,13 It has been shown that RAAS blockade prevents 
fibrosis. Aldosterone per se stimulates fibrosis by stimulating 
the production of plasminogen activator inhibitor (PAI-1) 
and transforming growth factor-β (TGF-β) and promoting 
inflammation and fibroblast growth and proliferation.14–19 PAI 
is an inhibitor of fibrinolysis and a regulator of extracellular 
matrix turnover.14 There are two types of PAI; PAI-2 is present 
in the placenta and PAI-1 is produced in the endothelium. On 
the other hand, TGF-β induces the production of extracellular 
matrix, stimulates fibroblast proliferation, and inhibits colla-
genase production, resulting in accumulation of extracellular 
matrix proteins, collagen, and fibrosis.17,18
Angiotensin II also plays an important role in the develop-
ment of fibrosis.1,20 Guo et al showed in a mice model that the 
ARB losartan and the ACE inhibitor enalapril decreased the 
levels of PAI-1 and reduced glomerular matrix deposition and 
glomerular mesangial cell activation.20 These effects are also 
evident with telmisartan. Yao et al and Tsunenari et al showed 
that telmisartan inhibited TGF-β and that this inhibition was 
related to the activation of PPAR-γ.21,22 Another study has 
recently demonstrated that telmisartan inhibits the activation 
of the pro-inflammatory nuclear transcription factor NF-κB 
independently of PPAR-γ.23
In an experimental study that was not related to blood 
pressure control or proteinuria, it was demonstrated that 
telmisartan protected the kidneys of rats from iodine contrast-
induced tubular damage. Because angiotensin II was elevated 
after tubular damage, the beneficial effect was attributed to 
angiotensin II blockade.24
In summary, the beneficial effects on vascular growth and 
fibrosis in the kidney via blockade of the AT1 receptor as 
well as the stimulation of PPAR-γ make telmisartan useful 
in the prevention of hypertensive renal disease.
Combination with other 
RAAS inhibitors
Accumulating evidence from several recent clinical trials 
indicates that the combination of an ARB and an ACE inhibi-
tor could produce more harm than benefit. The ONTARGET 
Study showed that telmisartan combined with ramipril 
decreased proteinuria but was associated with a decrease in 
the glomerular filtration rate.25,26 Other adverse effects were 
more common with the combination, such as hypotension 
and hyperkalemia.25,26 Acute renal failure is also more com-
mon with dual therapy.26 However, some have noted that 
combination therapy (dual ACE and AT1 receptor inhibition) International Journal of Nephrology and Renovascular Disease 2010:3 36
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is important in proteinuric glomerulopathies.27,28,29 In general, 
it is recommended to closely monitor patients that are started 
on combination therapy.
It was recently reported that the combination of an ACE 
inhibitor with telmisartan in patients with type 2 diabetes 
was beneficial in reducing the amount of albuminuria and 
  associated with less side effects like hyperkalemia and 
hypotension.30 The dose of telmisartan used in this study was 
40 mg daily compared with 80 mg daily in the ONTARGET 
study, which may have contributed to the decreased develop-
ment of side effects.
Combination treatment with the direct renin inhibitor 
aliskiren seems promising, but there are few studies currently 
available and it is recommended to be cautious until outcome 
studies become available.31
Use of telmisartan with the calcium channel blocker 
amlodipine has been shown to provide a notable improvement 
in blood pressure control in patients with stage 1 or 2 
hypertension.32 In addition, combination therapy was associ-
ated with a reduced rate of peripheral edema compared with 
amlodipine monotherapy. Patients were reported to have tol-
erated well the combination therapy. Regarding combination 
therapy with diuretics, Neldam et al prospectively studied 
telmisartan in combination with hydrochlorothiazide versus 
amlodipine plus hydrochlorothiazide in older patients ( or = 
60 years of age) with predominantly systolic hypertension.33 
The study showed that telmisartan plus hydrochlorothiazide 
provided higher systolic blood pressure control rates and 
lower adverse events and discontinuation of therapy, particu-
larly due to significantly less peripheral edema.
Telmisartan, like other ARBs, has been shown to be 
beneficial in diabetic nephropathy. Several studies have 
demonstrated a slowing in the progression of diabetic kidney 
disease and a decrease in the amount of proteinuria.34–36 
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Figure 2 Effects of telmisartan via blockade of the AT1 receptor.International Journal of Nephrology and Renovascular Disease 2010:3 37
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It has been reported that telmisartan is more effective in 
lowering proteinuria in hypertensive patients with overt 
diabetic nephropathy.35 This effect may be due, at least in 
part, to the inhibitory effects on ambulatory blood pres-
sure variability and sympathetic nerve activity. In addition, 
telmisartan has a longer duration of action on nighttime 
blood pressure reduction.35 Furthermore, recent studies 
have indicated that telmisartan may be better in reducing 
proteinuria when compared to losartan, another commonly 
used ARB.35,36
Conclusions
The importance of blood pressure control as a means to pre-
vent development or reduce progression of cardiovascular 
and kidney diseases has been firmly established. Like other 
blockers of the AT1 receptor, telmisartan is effective in 
reducing blood pressure when used alone or in combination 
with other antihypertensives.13 Its longer half-life, lipo-
philicity, and ability to stimulate PPAR-γ seem to provide 
additional cardiovascular and renal protective properties that 
make it an attractive agent for global cardiovascular risk 
reduction (Figure 2).
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